Evidence map›Paper›PMID 40521471›Full record

ArticleACS omega2025

Discovery of Palazestrant (OP-1250), a Potent and Orally Bioavailable Complete Estrogen Receptor Antagonist (CERAN) and Selective Estrogen Receptor Degrader (SERD).

Raymond A Ng, Susanna Barratt, Alison Parisian, Gopinath S Palanisamy, Samiron Phukan, Richard Sun, Brandon Robello, Guadalupe Peña, Judevin Sapugay, David Yeghikyan and 20 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

Raymond A NgOlema Oncology, 780 Brannan Street, San Francisco 94107, California, United States.ORCID https://orcid.org/0000-0002-2815-7718
Susanna BarrattOlema Oncology, 780 Brannan Street, San Francisco 94107, California, United States.
Alison ParisianOlema Oncology, 780 Brannan Street, San Francisco 94107, California, United States.
Gopinath S PalanisamyOlema Oncology, 780 Brannan Street, San Francisco 94107, California, United States.
Samiron PhukanAragen Life Sciences Private Ltd., Hyderabad 500076, India.ORCID https://orcid.org/0000-0002-5009-2340
Richard SunOlema Oncology, 780 Brannan Street, San Francisco 94107, California, United States.
Brandon RobelloOlema Oncology, 780 Brannan Street, San Francisco 94107, California, United States.
Guadalupe PeñaOlema Oncology, 780 Brannan Street, San Francisco 94107, California, United States.
Judevin SapugayOlema Oncology, 780 Brannan Street, San Francisco 94107, California, United States.
David YeghikyanOlema Oncology, 780 Brannan Street, San Francisco 94107, California, United States.
Chenbo WangOlema Oncology, 780 Brannan Street, San Francisco 94107, California, United States.
Samir Satish KherAragen Life Sciences Private Ltd., Hyderabad 500076, India.
Srinivasan ThangathirupathyAragen Life Sciences Private Ltd., Hyderabad 500076, India.
Robert MillikinOlema Oncology, 780 Brannan Street, San Francisco 94107, California, United States.
Guijun YuSynterys, Inc., Union City 94587, California, United States.
Teruki WatanabeAdesis, Inc., New Castle 19720, Delaware, United States.
Fei ZhouAdesis, Inc., New Castle 19720, Delaware, United States.
Brian RichOlema Oncology, 780 Brannan Street, San Francisco 94107, California, United States.
Alexis DuncanOlema Oncology, 780 Brannan Street, San Francisco 94107, California, United States.
Samuel E AndersenOlema Oncology, 780 Brannan Street, San Francisco 94107, California, United States.
Reena ChawlaOlema Oncology, 780 Brannan Street, San Francisco 94107, California, United States.
David R ZakDepartment of Cancer Biology, Loyola University Chicago Stritch School of Medicine, Maywood 60153, Illinois, United States.
Dirk A HeerdingOlema Oncology, 780 Brannan Street, San Francisco 94107, California, United States.
Brian R HearnOlema Oncology, 780 Brannan Street, San Francisco 94107, California, United States.
Geoffrey GreeneThe Ben May Department for Cancer Research, University of Chicago, Chicago 60637, Illinois, United States.
Cyrus L HarmonOlema Oncology, 780 Brannan Street, San Francisco 94107, California, United States.ORCID https://orcid.org/0009-0007-5428-0617
Leslie Hodges-GallagherOlema Oncology, 780 Brannan Street, San Francisco 94107, California, United States.
Peter J KushnerOlema Oncology, 780 Brannan Street, San Francisco 94107, California, United States.
Sean W FanningDepartment of Cancer Biology, Loyola University Chicago Stritch School of Medicine, Maywood 60153, Illinois, United States.ORCID https://orcid.org/0000-0002-9428-0060
David C MylesOlema Oncology, 780 Brannan Street, San Francisco 94107, California, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metastatic breast cancer (mBC) is a leading cause of cancer death in women. Most breast cancer patients are administered estrogen-receptor-targeted endocrine therapies to treat or prevent progressive metastatic disease. Development of endocrine resistance through acquisition of mutations in the estrogen receptor gene,

Identifiers

PMID40521471
PMCPMC12163657

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.